These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32382233)

  • 1. Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C: a meta-analysis.
    Lui FH; Moosvi Z; Patel A; Hussain S; Duong A; Duong J; Nguyen DL
    Ann Gastroenterol; 2020; 33(3):293-298. PubMed ID: 32382233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis.
    Frazzoni L; Sikandar U; Metelli F; Sadalla S; Mazzella G; Bazzoli F; Fuccio L; Azzaroli F
    J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33920785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ
    J Hepatol; 2017 Dec; 67(6):1204-1212. PubMed ID: 28802876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.
    Conti F; Buonfiglioli F; Scuteri A; Crespi C; Bolondi L; Caraceni P; Foschi FG; Lenzi M; Mazzella G; Verucchi G; Andreone P; Brillanti S
    J Hepatol; 2016 Oct; 65(4):727-733. PubMed ID: 27349488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria.
    Ochi H; Hiraoka A; Hirooka M; Koizumi Y; Amano M; Azemoto N; Watanabe T; Yoshida O; Tokumoto Y; Mashiba T; Yokota T; Abe M; Michitaka K; Hiasa Y; Joko K
    J Gastroenterol; 2021 Jan; 56(1):90-100. PubMed ID: 33278003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
    Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
    J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma.
    Tajiri K; Ito H; Kawai K; Kashii Y; Hayashi Y; Murayama A; Minemura M; Takahara T; Shimizu Y; Yasuda I
    World J Hepatol; 2022 Jun; 14(6):1190-1199. PubMed ID: 35978673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.
    Vallet-Pichard A; Correas JM; Dorival C; Zoulim F; Tran A; Bourlière M; Calès P; Guyader D; Bronowicki JP; Larrey D; Hezode C; Loustaud-Ratti V; Gournay J; de Ledinghen V; Asselah T; Ganne N; Metivier S; Chazouillères O; Leroy V; Rosa I; Samuel D; Mathurin P; Cagnot C; Fontaine H; Carrat F; Pol S;
    Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101459. PubMed ID: 32595103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
    Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA
    Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis.
    You MW; Kim KW; Shim JJ; Pyo J
    J Gastroenterol Hepatol; 2021 Mar; 36(3):601-608. PubMed ID: 32875681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
    Sapena V; Enea M; Torres F; Celsa C; Rios J; Rizzo GEM; Nahon P; Mariño Z; Tateishi R; Minami T; Sangiovanni A; Forns X; Toyoda H; Brillanti S; Conti F; Degasperi E; Yu ML; Tsai PC; Jean K; El Kassas M; Shousha HI; Omar A; Zavaglia C; Nagata H; Nakagawa M; Asahina Y; Singal AG; Murphy C; Kohla M; Masetti C; Dufour JF; Merchante N; Cavalletto L; Chemello LL; Pol S; Crespo J; Calleja JL; Villani R; Serviddio G; Zanetto A; Shalaby S; Russo FP; Bielen R; Trevisani F; Cammà C; Bruix J; Cabibbo G; Reig M
    Gut; 2022 Mar; 71(3):593-604. PubMed ID: 33741640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
    Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
    Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
    Singal AG; Lim JK; Kanwal F
    Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.
    Saraiya N; Yopp AC; Rich NE; Odewole M; Parikh ND; Singal AG
    Aliment Pharmacol Ther; 2018 Jul; 48(2):127-137. PubMed ID: 29851093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis.
    El Kassas M; Funk AL; Salaheldin M; Shimakawa Y; Eltabbakh M; Jean K; El Tahan A; Sweedy AT; Afify S; Youssef NF; Esmat G; Fontanet A
    J Viral Hepat; 2018 Jun; 25(6):623-630. PubMed ID: 29274197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study.
    Gorgen A; Galvin Z; Huang AC; Vinaixa C; O'Rourke JM; Francoz C; Hansen BE; Durand F; Elsharkawy AM; Shah T; Berenguer M; Rubin A; Calatayud D; Mehta N; Terrault NA; Lilly LB; Selzner N; Sapisochin G
    Transplantation; 2020 Oct; 104(10):2087-2096. PubMed ID: 31978002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.
    ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: stanislas.pol@aphp.fr
    J Hepatol; 2016 Oct; 65(4):734-740. PubMed ID: 27288051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma.
    Chen YS; Huang KH; Wang PM; Chuang CH; Yong CC; Liu YW; Huang PY; Yao CC; Lin YP; Tsai MC
    Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208582
    [No Abstract]   [Full Text] [Related]  

  • 20. Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Ikeda K; Kawamura Y; Kobayashi M; Kominami Y; Fujiyama S; Sezaki H; Hosaka T; Akuta N; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Dig Dis Sci; 2017 Oct; 62(10):2932-2942. PubMed ID: 28884320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.